Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral Arsenic Trioxide-based Induction in Newly Diagnosed APL
NCT03624270Phase 2Unknown
- Sponsor
- The University of Hong Kong
- Start
- Aug 2018
- Primary completion
- Sep 2023
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of arsenic trioxide in acute promyelocytic leukemia (APL), sponsored by The University of Hong Kong. Primary endpoints: Overall Survival at 60 months and Leukemia-Free Survival at 60 months. Status: unknown.
02
Drugs
arsenic trioxide
03
Conditions
acute promyelocytic leukemia (APL)
Beyond the preview
Go deeper on NCT03624270.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03624270.